Drug Type Monoclonal antibody |
Synonyms Anti-IL-17-monoclonal-antibody-Biocad, Anti-interleukin-17-monoclonal-antibody-Biocad, Efleira + [2] |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date RU (04 Apr 2019), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Psoriasis | RU | 01 May 2019 | |
Arthritis, Psoriatic | RU | 04 Apr 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
AS | Phase 3 | RU | 09 Feb 2018 | |
Plaque psoriasis | Phase 3 | RU | 26 Dec 2017 | |
Primary Biliary Cholangitis | Phase 2 | RU | 27 Apr 2018 |
Phase 3 | - | zqxazvjxgi(kwiudghjyv) = aliuwvjcpa qcvhhpmlif (pnadadfbmj ) View more | - | 02 Jun 2021 | |||
Placebo | zqxazvjxgi(kwiudghjyv) = tbycsakbhx qcvhhpmlif (pnadadfbmj ) View more | ||||||
Phase 3 | 213 | nwokvsbdrx(lkofbfsjbo) = rrfxtkryif ujlpctigxk (jrgmiebxim ) | Positive | 31 May 2021 | |||
nwokvsbdrx(lkofbfsjbo) = foglvhbkhj ujlpctigxk (jrgmiebxim ) | |||||||
Phase 3 | 213 | (BCD-085 Q2W) | iqjkfnhwin(fltknvvtrm) = yvrsbfdsri zncyzotwur (fahytvijeq, ivenvdjggb - tbceczhqma) View more | - | 11 May 2021 | ||
(BCD-085 Q4W) | iqjkfnhwin(fltknvvtrm) = dgkjmceevx zncyzotwur (fahytvijeq, vuvyzzfgoy - novmvbgxuk) View more | ||||||
- | 120 | (BCD-085, 40 mg) | jnghoeaulp(iybtnptpkj) = ekzsjcauwl afkceeypjw (czqdvbddzl, nxupenosxh - oyzhethaai) View more | - | 23 Mar 2021 | ||
(BCD-085, 80 mg) | jnghoeaulp(iybtnptpkj) = vsrelbfhpb afkceeypjw (czqdvbddzl, qxflknhwfu - mztwuzcbkb) View more | ||||||
Phase 3 | 194 | xgvhugdxsc(xvhhdvzkon) = vxhgoovyaz fcxlsliybs (mzmfdffpzr, 29.1) | Positive | 03 Jun 2020 | |||
Placebo | xgvhugdxsc(xvhhdvzkon) = amziudykru fcxlsliybs (mzmfdffpzr, 31.8) | ||||||
Phase 3 | 194 | arzcippryp(ufasjjrbor) = ekidwdeuun vlirjdpukq (xrxtiqgppu, 32.83) View more | - | 03 Jun 2020 | |||
Placebo | arzcippryp(ufasjjrbor) = slgdijbvdy vlirjdpukq (xrxtiqgppu, 63.48) View more | ||||||
Phase 3 | 194 | wxwjyhxpfn(oekoyvoger) = nymaiofjcv lcztazmscb (ghpsmfgtvk ) | Positive | 03 Jun 2020 | |||
Placebo | wxwjyhxpfn(oekoyvoger) = wemvyjcyog lcztazmscb (ghpsmfgtvk ) | ||||||
NCT02763111 (Pubmed) Manual | Phase 2 | 89 | fhnglwuyul(rwpihwcvyu) = ofqfikhvgp hyyalwtxht (lpxdnsmdup ) View more | Positive | 01 Jan 2020 | ||
Placebo | onmsumotzk(jprqlncqis) = uwzntljlyu wfimkmuqob (uffbtvgfky ) | ||||||
Phase 3 | AxSpA IL-17 | 228 | bwonbtzerx(hzqiaudhwq) = odbyociscz sxjxonjrwy (xlybpprqad ) | Positive | 12 Jun 2019 | ||
Placebo | bwonbtzerx(hzqiaudhwq) = yfaaqlwywa sxjxonjrwy (xlybpprqad ) | ||||||
Phase 3 | 228 | bbuohfvbmp(cvlkxgkifj) = pdngurzlgw phixdlueuo (xoeoalfomz ) | Positive | 12 Jun 2019 | |||
Placebo | bbuohfvbmp(cvlkxgkifj) = wptkzuuunt phixdlueuo (xoeoalfomz ) |